RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
36 hedge funds and large institutions have $21.6M invested in RVL Pharmaceuticals plc Ordinary Shares in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
6% more funds holding
Funds holding: 34 → 36 (+2)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
58% less capital invested
Capital invested by funds: $50.9M → $21.6M (-$29.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$640K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$350K |
| 3 |
Morgan Stanley
New York
|
+$197K |
| 4 |
Bank of New York Mellon
New York
|
+$170K |
| 5 |
HW
Hancock Whitney
Gulfport,
Mississippi
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.15M |
| 2 |
BC
Broadfin Capital
New York
|
-$1.62M |
| 3 |
NC
Nexthera Capital
New York
|
-$935K |
| 4 |
Millennium Management
New York
|
-$657K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$428K |
RVLP Hedge Fund Activity: Q1 2019 in Review
36 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2019, worth a combined $21.6M — down 58% from $50.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RVLP positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was State Street, adding an estimated $640K. The largest seller was Deerfield Management, cutting an estimated $2.15M.
- 36 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2019, up from 34 in Q4 2018.
- Funds reported $21.6M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2019, down 58% quarter-over-quarter.
- 9 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2019 and 7 closed out, a net change of +2 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2019 was State Street, an estimated $640K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2019 was Deerfield Management, an estimated $2.15M sold.
Based on aggregated 13F filings for Q1 2019.